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Background: Bipolar disorders (BD) are of particular public health significance as they are 
prevalent, severe and disabling, and often associated with elevated risks of premature   mortality. 
The aim of this concise overview is to investigate the role of asenapine in the treatment of manic 
and mixed states associated with BD type 1 disorder.
Method: MedLine, Excerpta Medica and PsycINFO searches were performed to identify papers 
in English published over the past 7 years. Search terms were “asenapine”, “manic” OR “mixed 
states”, “bipolar I disorder”. Subjects included in this study suffered from BD type 1 disorder.
Results: To date, only four studies of asenapine for the treatment of manic or mixed episodes 
associated with BD type 1 have been published.
Conclusion: Research indicates that asenapine is generally well-tolerated, and that asenapine 
is efficacious and not inferior to olanzapine in the treatment of mixed or manic episodes associ-
ated with BD type 1 in the short-term and long-term.
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Introduction
Bipolar disorders (BD) are of particular public health significance as they are prevalent, 
severe and disabling, and often associated with elevated risks of premature mortality, 
adverse medical outcomes, accidents, and complications from comorbid substance 
use disorders.1
The World Health Organization reported, in 2001, that bipolar disorder was the fifth 
cause of years lived with disability among young adults. BD is characterized by periods 
of mania, depression, or mixed episodes, often multiple times during a lifetime. Mania 
is the most characteristic phase of bipolar disorder, and a major cause of disability, 
stigma and cognitive impairment. Lithium is the traditional treatment option, but the 
majority of patients do not respond to lithium monotherapy. Other drugs have been 
introduced in recent years, such as the anticonvulsants valproate and carbamazepine, 
some typical antipsychotics (eg, haloperidol, chlorpromazine), atypical antipsychotics 
(such as quetiapine, olanzapine, risperidone, ziprasidone, aripiprazolo and clozapine), 
and benzodiazepines (eg, lorazepam and clonazepam).2
Therapy for mood disorders is a major problem in psychiatry despite the avail-
ability of effective treatments. Mood disorders frequently remain undiagnosed and, 
even if recognized, treatment duration and dosage are often inadequate and adherence 
to the medication regimen is poor.3 Greater antidepressant adherence has been linked 
to greater response and remission among depressed subjects,3 whereas nonadher-
ence has been shown to be related to less improvement of depressive symptoms and Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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greater relapse/recurrence of depression.4–7 It is estimated that 
  nonadherence ranges from 10% to 60% in mood disorders, 
with a median of 40%.8 However, according to Lingam and 
Scott,8 this topic is understudied, and only 1%–2% of all 
publications on the treatment of affective disorders explore 
factors associated with medication nonadherence.
BD is associated with high levels of long-term morbid-
ity, comorbidity, hospitalization, disability, and increased 
mortality rates resulting from suicide, accidents, adverse 
outcomes of comorbid substance use and abuse, and medical 
illnesses.9–13 Nonadherence with medication regimens appears 
to contribute substantially to worse outcomes and possibly to 
treatment failures among patients with BD. Antipsychotics are 
commonly used in the treatment of BD. All currently approved 
antipsychotic drugs block dopamine D2 receptors, and all 
atypical antipsychotics are also more potent antagonists of 
the 5-hydroxytryptamine receptor 2A (5-HT2A).14
Asenapine (Saphris®) is a second-generation antipsy-
chotic, which received regulatory approval in August 2009 
by the US Food and Drug Administration (FDA) for the 
acute treatment of schizophrenia and for the acute treatment 
of manic or mixed episodes associated with BD-I disorder 
in adults. Originally developed by Organon, asenapine was 
initially known as ORG 52222. The first substantive mention 
of the molecule in the published literature is an animal study 
published in 1990 that suggested that it had antipsychotic and 
anxiolytic potential related to dopamine and serotonin recep-
tor antagonism. It was investigated originally in Europe and 
Japan in intravenous and oral formulations, but because of 
low bioavailability and high hepato-gastrointestinal first-pass 
metabolism of the oral formulation, a sublingual dosage form 
was developed. The development of sublingual asenapine 
began in 1996 for the treatment of schizophrenia, and in 
2004 for the treatment of bipolar disorder. Asenapine is 
classified as a dibenzo-oxepino pyrrole and has properties 
that are most similar to those of quetiapine, olanzapine, and 
clozapine.15
As with other antipsychotic agents, asenapine exhibits 
a higher binding affinity for the 5HT2A receptor compared 
with D2 receptors. Moreover, asenapine has a broad range 
of effects on other neurotransmitter systems including 
5-HT2c, 5-HT7, 5-HT2b, 5-HT6, 5-HT1a, 5-HT1b, α2b, 
α1a, α2a, α2c, D3, D4, D2l, D1, D2s, and H2 receptors. 
One major difference between asenapine and most other 
atypical antipsychotics (except for risperidone, ziprasidone 
and aripiprazolo) is that it exhibits little muscarinic recep-
tor antagonist effects, which may produce a less cognitively 
deleterious profile, but it may result in weight gain. Given 
that D2 receptor occupancy has been deemed as vital for 
antipsychotic efficacy, it is important to note that 5 mg tab-
lets result in roughly 75% D2 occupancy, while occupancy 
is 85% with 10 mg tablets.
The sublingual administration results in a rapid absorp-
tion with peak plasma concentrations within 0.5–1.5 hours 
and moderate (35%) bioavailability. This is in the low to 
mid-range of other antipsychotics, which exhibit 20%–70% 
Table 3 randomized controlled trials of asenapine versus olanzapine and placebo: adverse events
Study Asenapine dose Olanzapine dose Trial (weeks) Treatment-related adverse events Discontinued Discontinued because of adverse events Discontinued because of lack of efficacy
Olanzapine Asenapine Placebo Olanzapine Asenapine Placebo Olanzapine Asenapine Placebo Olanzapine Asenapine Placebo
Mcintyre et al18  
(Ares 7501005;  
clinical trial  
registry number:  
NcT00159796)
5–10 mg BiD FLeX  
(Mean: 18.2 mg)
5–20 mg QD  
(Mean: 15.8 mg)
3 52.9% 60.8% 36.2% 30.9% 37.1% 38.5% 4.2% 10.3% 6.7% 5.8% 8.2% 16.3%
Mcintyre et al20  
(Ares 7501004;  
NcT00159744)
BiD FLeX (Mean:  
18.4 mg)
5–20 mg QD  
(Mean: 15.9 mg)
3 46.8% 55.1% 27.6% 21.5% 33.0% 41.8% 3.4% 9.2% 4.1% 6.3% 7.6% 14.3%
Mcintyre et al21  
(Ares 7501006;  
registry  
#NcT00143182)
5–10 mg BiD FLeX 5–20 mg QD 9 (extension  
study)
64% (53%)* 65% – 36.2% 38.1% (46.8%)* – 9.6% 13.3% (19.2%)* – 3.9% 3.3% (5.3%)* –
Mcintyre et al19  
(A7501007,  
NcT00159783)
5–10 mg BiD FLeX  
(Mean: 15.7 ± 4.1 mg  
placebo/asenapine group,  
16.3 ± 3.7 mg asenapine  
group)
5–20 mg QD  
(Mean: 15.4 ± 4.0 mg)
40 (extension  
study)
61.7% (53.1%)* 70.9% – 36.4% 34.2% (59.4%)* – 8.4% 8.9% (15.6%)* – 2.8% 2.5% (3.1%)* –
Note: *Placebo/Asenapine group. 
Abbreviations: LOcF, last observation carried forward; MMrM, mixed model for repeated measures; Oc, observed case; cGi-BP, clinical Global impression for Bipolar 
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bioavailability at appropriate doses. The primary   metabolic 
pathways of asenapine are direct glucuronidation by 
glucuronidyl transferases and oxidative metabolism by 
cytochrome P450 isoenzymes. Thus, coadministration of 
asenapine with known inhibitors, inducers or substrates of 
these metabolic pathways, including the CYP1A2 inhibi-
tor fluvoxamine, can alter the metabolism of asenapine. 
  However such interactions are not uncommon among atypi-
cal antipsychotics. Importantly, given the high incidence 
of smoking, smoking during administration does not alter 
the pharmacokinetics of asenapine. The reduced bioavail-
ability via oral consumption means, however, that eating 
or drinking within 10 minutes can alter the bioavailability 
of asenapine.16
The aim of this concise overview is to investigate the role 
of asenapine, a new second-generation antipsychotic agent, 
in the treatment of manic and mixed states associated with 
BD-I disorder.
Methods
In order to provide a new, timely and concise mini-review 
of asenapine in the treatment of manic and mixed states 
associated with BD disorder, we performed careful MedLine, 
Excerpta Medica and PsycInfo searches to identify papers 
published in English over the past 7 years. Search terms were 
“asenapine”, “manic”, “mixed states”, “bipolar I disorder”. 
Each term was also cross-referenced with the others using 
the MeSH method (Medical Subjects Headings).
The selection of trials for inclusion in the review was 
firstly performed by the principal reviewer (MP) followed 
by a further independent (blind to each other) review by the 
other authors after employing the search strategy described 
previously. Where a title or abstract appeared to describe a 
trial eligible for inclusion, the full article was obtained and 
inspected to assess relevance to this review based on the 
inclusion criteria. The principal author independently decided 
whether these met the review criteria. No blinding to the 
names of authors, institutions and journal of publication took 
place. Any discrepancies between the two reviewers were 
resolved by consultations with senior colleagues. When this 
proved impossible, we sought further information and, in 
the interim, added these trials to the ‘Awaiting assessment’ 
list. The reference list was further modified on the basis of 
comments from peer reviewers.
Patients included in this review were adult ($18 years old) 
with a current Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV) primary diagnosis of 
bipolar I disorder who were experiencing manic or mixed 
episodes.
Clinical efficacy and safety
The FDA approved asenapine based on the efficacy outcomes 
from four clinical trials (two studies of acute schizophrenia 
and two studies of mania/mixed episodes of BD-I). These 
pivotal trials were supported by a number of other studies 
that also contributed safety data. The briefing documents, 
Table 3 randomized controlled trials of asenapine versus olanzapine and placebo: adverse events
Study Asenapine dose Olanzapine dose Trial (weeks) Treatment-related adverse events Discontinued Discontinued because of adverse events Discontinued because of lack of efficacy
Olanzapine Asenapine Placebo Olanzapine Asenapine Placebo Olanzapine Asenapine Placebo Olanzapine Asenapine Placebo
Mcintyre et al18  
(Ares 7501005;  
clinical trial  
registry number:  
NcT00159796)
5–10 mg BiD FLeX  
(Mean: 18.2 mg)
5–20 mg QD  
(Mean: 15.8 mg)
3 52.9% 60.8% 36.2% 30.9% 37.1% 38.5% 4.2% 10.3% 6.7% 5.8% 8.2% 16.3%
Mcintyre et al20  
(Ares 7501004;  
NcT00159744)
BiD FLeX (Mean:  
18.4 mg)
5–20 mg QD  
(Mean: 15.9 mg)
3 46.8% 55.1% 27.6% 21.5% 33.0% 41.8% 3.4% 9.2% 4.1% 6.3% 7.6% 14.3%
Mcintyre et al21  
(Ares 7501006;  
registry  
#NcT00143182)
5–10 mg BiD FLeX 5–20 mg QD 9 (extension  
study)
64% (53%)* 65% – 36.2% 38.1% (46.8%)* – 9.6% 13.3% (19.2%)* – 3.9% 3.3% (5.3%)* –
Mcintyre et al19  
(A7501007,  
NcT00159783)
5–10 mg BiD FLeX  
(Mean: 15.7 ± 4.1 mg  
placebo/asenapine group,  
16.3 ± 3.7 mg asenapine  
group)
5–20 mg QD  
(Mean: 15.4 ± 4.0 mg)
40 (extension  
study)
61.7% (53.1%)* 70.9% – 36.4% 34.2% (59.4%)* – 8.4% 8.9% (15.6%)* – 2.8% 2.5% (3.1%)* –
Note: *Placebo/Asenapine group. 
Abbreviations: LOcF, last observation carried forward; MMrM, mixed model for repeated measures; Oc, observed case; cGi-BP, clinical Global impression for Bipolar 
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prepared by the FDA, reported 51 completed trials and 12 
  ongoing clinical trials in the asenapine clinical program. Of 
these, 29 are clinical pharmacology studies in healthy subjects 
and subjects with renal or hepatic impairment, and eight are 
clinical pharmacology studies in subjects with schizophre-
nia or schizoaffective disorder. This leaves 14 completed 
Phase II and III studies of asenapine in schizophrenia and 
bipolar mania. Very little of this research has been published 
in peer-reviewed journals, and only some has appeared in 
posters and presentations. However, the briefing documents 
available do provide sufficient detail to allow an appraisal 
of the evidence regarding the efficacy and tolerability of 
asenapine.17
Clinical trials
To date, only four studies of asenapine for the treatment of 
manic or mixed episodes associated with BD-I have been 
published. These are four progressive trials, conducted by 
McIntyre et al, that analyzed asenapine’s efficacy, toler-
ability, and safety in both the short-term and long-term18–21 
(Tables 1–3).
Eligible patients were adults who met Diagnostic and 
Statistical Manual, Fourth Edition (DSM-IV) criteria for 
BD-I and who were experiencing manic or mixed episodes. 
The authors conducted two identical 3-week, randomized, 
double-blind, placebo controlled trials with 488 and 489 
patients respectively. They were randomly assigned to 
  flexible-dose sublingual asenapine (5 or 10 mg), oral olan-
zapine (5–20 mg) or placebo. The patients who completed the 
trials were eligible for a 9-week, double-blind extension study 
(504 patients) that did not include a placebo arm and, finally, 
those who completed this extension study could enter a 
40-week extension study (218 patients). Efficacy evaluations 
were made using the Young Mania Rating Scale (YMRS).22 
Tolerability and safety assessment included adverse effects, 
physical examinations, extrapyramidal symptom ratings, and 
laboratory tests.
In both studies, no significant differences were identified 
between olanzapine and asenapine when compared with 
placebo in the YMRS total score. In the first study, YMRS 
response and remission rates with olanzapine, but not with 
asenapine, were greater than placebo but, in the second study, 
both drugs, olanzapine and asenapine were superior to pla-
cebo. Discontinuation rates (for reasons such as extrapyrami-
dal-related adverse effects) were generally low in both trials, 
with no significant differences between the groups. In both tri-
als, a poor weight gain profile was observed in the olanzapine 
group when compared with the asenapine and placebo groups. 
Changes from baseline in metabolic chemistries, laboratory 
tests and vital signs were generally small and not clinically 
relevant, although prolactin levels were slightly greater with 
olanzapine than with asenapine.18–21,23 Long-term efficacy 
and safety were investigated during the 9-week and 40-week 
double blind extension studies. In these studies, asenapine 
was not inferior to olanzapine for changes from baseline in 
YMRS total score, but clinically significant weight gain was 
greater with olanzapine than asenapine.
The use of asenapine was also studied in a trial as adjunc-
tive treatment for acute mania associated with BD-I. In this 
randomized, controlled trial, adjunctive asenapine signifi-
cantly improved the symptoms of BD-I in adult patients not 
fully responsive to pre-existing mood stabilizers.24
Conclusion
Research indicates that asenapine is generally well-tolerated, 
with no significant differences between groups in terms of 
adverse events or extrapyramidal symptoms in the short-
term and long-term. In all four trials, the risk for clinically 
significant weight gain was greater with olanzapine than with 
asenapine, and that risk increased with extended treatment. 
Changes from baseline in metabolic chemistries, laboratory 
tests and vital signs were generally small and not clinically 
relevant, although prolactin levels were slightly greater with 
olanzapine than with asenapine. Compared with olanzapine, 
asenapine was less likely to cause dry mouth and weight 
gain, but more likely to cause dizziness, nausea, akathisia, 
and oral hypoesthesia.
In conclusion, this review indicates that asenapine is 
efficacious and not inferior to olanzapine in the treatment 
of mixed or manic episodes associated with BD-I in the 
short-term and long-term. It is also well-tolerated, with a 
low incidence of side effects, the most common of which are 
somnolence, akathisia, dizziness, nausea, weight gain and 
oral hypoesthesia due to its sublingual administration. Most 
adverse events were mild to moderate in severity. Moreover it 
seems that asenapine’s weight gain profile is better than that 
associated with several other second-generation antipsychot-
ics, including olanzapine. Importantly, it has no appreciable 
effect on metabolic laboratory parameters.
Asenapine is administered through a sublingual route 
which could be an advantage in a patient population that 
refuses to swallow. The disadvantages are twice-daily 
dosing (because an increase in dosing frequencies seem to 
have a negative effect on the compliance of patients to the Neuropsychiatric Disease and Treatment
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  treatment), and there is also a need to avoid food and drink for 
10 minutes after dosing. Because of the small number of trials 
to date, the therapeutic impact of asenapine on the treatment 
of bipolar disorder requires further clinical investigation.
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